DrugPatentWatch Database Preview
Drugs in Development Information for Dalotuzumab
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Dalotuzumab?
Dalotuzumab is an investigational drug.
There have been 13 clinical trials for Dalotuzumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2008.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Colorectal Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Ariad Pharmaceuticals, and Alliance for Clinical Trials in Oncology.
Summary for Dalotuzumab
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2008-03-01) |
| Vendors | 2 |
Recent Clinical Trials for Dalotuzumab
| Title | Sponsor | Phase |
|---|---|---|
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | Merck Sharp & Dohme Corp. | Phase 2 |
| A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | Merck Sharp & Dohme Corp. | Phase 2 |
| Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) | Merck Sharp & Dohme Corp. | Phase 1 |
Clinical Trial Summary for Dalotuzumab
Top disease conditions for Dalotuzumab
Top clinical trial sponsors for Dalotuzumab
US Patents for Dalotuzumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
